SAFETY AND TOLERABILITY OF ONCE-DAILY ORAL KALLIKREIN INHIBITOR BCX7353 IN PHASE 3 APEX-2 HAE STUDY

被引：3
|
作者：
Riedl, M.
Lumry, W.
Banerji, A.
Aygoren-Pursun, E.
Bernstein, J.
Maurer, M.
Cicardi, M.
Christiansen, S.
Zuraw, B.
Dobo, S.
Cornpropst, M.
Iocca, H.
Nagy, E.
Murray, S.
Collis, P.
Sheridan, W.
Johnston, D.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2019年 / 123卷 / 05期
关键词：
D O I：
10.1016/j.anai.2019.08.258
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P154
引用
收藏
页码：S28 / S29
页数：3
相关论文
共 50 条
  • [31] Efficacy, safety, and tolerability of once-daily abediterol in patients with stable, persistent asthma: a Phase II, randomized, 7-day, crossover study
    Beier, Jutta
    Fuhr, Rainard
    Seoane, Beatriz
    Massana, Eric
    de Miquel, Gonzalo
    Pujol, Helena
    Ruiz, Sandrine
    [J]. PHARMACOLOGY RESEARCH & PERSPECTIVES, 2017, 5 (05):
  • [32] A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids
    Edward Kerwin
    Steven Pascoe
    Zelie Bailes
    Robert Nathan
    David Bernstein
    Ronald Dahl
    Robyn von Maltzahn
    Kevin Robbins
    Andrew Fowler
    Laurie Lee
    [J]. Respiratory Research, 21
  • [33] Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers
    Leber, Andrew
    Hontecillas, Raquel
    Juni, Nuria Tubau
    Bassaganya-Riera, Josep
    [J]. ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4631 - 4632
  • [34] Efficacy and safety of Once-Daily Vilanterol/Fluticasone furoate MDI in persistent asthma: Phase 3 OD-INHALE Study
    Kumar, Avdhesh
    Jain, Manish Kumar
    Barge, Vijaykumar Bhagwan
    Kumar, Raghumanda Sunil
    Gupta, Neeraj
    Yadav, Harendra
    Pal, Amitava
    Redkar, Vivek Eknath
    Mondal, Asish
    Rathore, Rahul Kumar
    Daultani, Pavankumar
    Jaiswal, Ashok
    Mehta, Ravi T.
    [J]. JOURNAL OF ASTHMA, 2024,
  • [35] Safety, Tolerability, and Pharmacokinetics of the HIV Integrase Inhibitor Dolutegravir Given Twice Daily With Rifampin or Once Daily With Rifabutin: Results of a Phase 1 Study Among Healthy Subjects
    Dooley, Kelly E.
    Sayre, Patrick
    Borland, Julie
    Purdy, Elizabeth
    Chen, Shuguang
    Song, Ivy
    Peppercorn, Amanda
    Everts, Stephanie
    Piscitelli, Stephen
    Flexner, Charles
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 (01) : 21 - 27
  • [36] Tolerability of indacaterol, a novel once-daily β2-agonist, in patients with asthma:: a randomized, placebo-controlled, 28-day safety study
    Yang, William H.
    Martinot, Jean Benoit
    Pohunek, Petr
    Beier, Jutta
    Magula, Daniel
    Cameron, Ray
    Owen, Roger
    Higgins, Mark
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 99 (06) : 555 - 561
  • [37] A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (20 mg Once-Daily) Compared to Lansoprazole (30 mg Once-Daily) in Patients With Erosive Esophagitis
    Iwakiri, Katsuhiko
    Umegaki, Eiji
    Hiramatsu, Naoki
    Sakurai, Yuuichi
    Hori, Tetsuharu
    Kudou, Kentarou
    Nishimura, Akira
    Ashida, Kiyoshi
    [J]. GASTROENTEROLOGY, 2014, 146 (05) : S741 - S741
  • [38] Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-875, a Novel GPR40 Agonist, Following Once-Daily Oral Administration for 2 Weeks in Type 2 Diabetic Patients
    Leifke, Eckhard
    Wu, Jingtao
    Viswanathan, Prabhakar
    Kipnes, Mark S.
    Vakilynejad, Majid
    [J]. DIABETES, 2011, 60 : A114 - A115
  • [39] A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors (vol 31, pg 742, 2013)
    Shapiro, Geoffrey I.
    McCallum, Stewart
    Adams, Laurel M.
    Sherman, Laurie
    Weller, Steve
    Swann, Suzanne
    Keer, Harold
    Miles, Dale
    Mueller, Thomas
    Rabe, Daniel C.
    Cecchi, Fabiola
    Bottaro, Donald P.
    LoRusso, Patricia
    [J]. INVESTIGATIONAL NEW DRUGS, 2015, 33 (06) : 1292 - 1292
  • [40] Open-label phase 2 study to explore durability of effect and safety of once-daily oral ampreloxetine (TD-9855), a norepinephrine reuptake inhibitor, for symptomatic treatment of neurogenic orthostatic hypotension in subjects with synucleinopathies
    Kaufmann, H.
    Biaggioni, I.
    Wang, W.
    Haumann, B.
    Vickery, R.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 36 - 36
12345